KRS Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

KRS Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$781K	Hold	1,572	–	–	0.36%	48
2026 Q1	$702K	Hold	1,572	–	–	0.43%	50
2025 Q4	$713K	Hold	1,572	–	–	0.41%	53
2025 Q3	$616K	Sell	1,572 -50	-3%	-$20.9K	0.37%	56
2025 Q2	$722K	Sell	1,622 -115	-7%	-$53K	0.48%	44
2025 Q1	$842K	Sell	1,737 -15	-0.9%	-$6.99K	0.67%	31
2024 Q4	$706K	Hold	1,752	–	–	0.5%	42
2024 Q3	$815K	Sell	1,752 -15	-0.8%	-$7.21K	0.59%	34
2024 Q2	$828K	Hold	1,767	–	–	0.62%	33
2024 Q1	$739K	Hold	1,767	–	–	0.6%	38
2023 Q4	$719K	Hold	1,767	–	–	0.67%	39
2023 Q3	$614K	Hold	1,767	–	–	0.65%	43
2023 Q2	$622K	Sell	1,767 -25	-1%	-$8.42K	0.62%	44
2023 Q1	$565K	Buy	1,792 +200	+13%	+$60K	0.64%	44
2022 Q4	$460K	Buy	1,592 +200	+14%	+$61K	0.63%	50
2022 Q3	$403K	Buy	1,392 +125	+10%	+$36K	0.56%	55
2022 Q2	$357K	Hold	1,267	–	–	0.51%	67
2022 Q1	$330K	Buy	1,267 +150	+13%	+$35.6K	0.36%	82
2021 Q4	$245K	Buy	+1,117	New	+$217K	0.21%	104

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

CTB

Country Trust Bank Bloomington, Illinois $5.71B AUM 25.48% 1-Year Est. Return

CNB

Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return

GIA

Gateway Investment Advisers Cincinnati, Ohio $10.1B AUM 40.26% 1-Year Est. Return

IFM Investors Melbourne, Australia $15.1B AUM 40.57% 1-Year Est. Return

KRS Capital Management's VRTX Position: Q2 2026 in Review

KRS Capital Management held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 1,572 shares worth $781K. The position accounts for 0.36% of the portfolio, ranked #48.

KRS Capital Management first reported a position in VRTX in Q4 2021 and has held it in 19 quarters since. The position peaked at $842K in Q1 2025. 334 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

KRS Capital Management held 1,572 shares of Vertex Pharmaceuticals worth $781K as of Q2 2026.
KRS Capital Management left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.36% of KRS Capital Management's portfolio in Q2 2026, its #48 holding.
KRS Capital Management first reported a position in Vertex Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
KRS Capital Management's Vertex Pharmaceuticals position peaked at $842K in Q1 2025.
334 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on KRS Capital Management's 13F filing for Q2 2026, filed 20 Jul 2026.